🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Siwen Hu‐Lieskovan

University of Utah

ORCID: 0000-0001-5836-4710

Also affiliated with Huntsman Cancer Institute, University of Utah Health Care

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile
0.944Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome

Frontiers in Immunology(2023)10.3389/fimmu.2023.1229823
Top 21%
0.944DataRank
Top 21%26 citations

Jordan P. McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami +10 more

Papers

Driven by 19 papers — median percentile 79. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437
N/A
6.5DataRank · unranked
846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02498-y
N/A
4.8DataRank · unranked
171 citations

Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia +28 more

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

Nature Communications(2020)10.1038/s41467-019-12901-3
N/A
2.5DataRank · unranked
96 citations

Justin D. Saco, Felix B. Salazar, Jennifer Tsoi, Paige Krystofinski, Cristina Puig-Saus +16 more

A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome

Frontiers in Immunology(2023)10.3389/fimmu.2023.1229823
Top 21%
0.944DataRank
Top 21%26 citations

Jordan P. McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami +10 more

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9502
N/A
0.464DataRank · unranked
21 citations

James Moon, Zeynep Eroglu, Siwen Hu‐Lieskovan, William E. Carson, David A. Wada +15 more

Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008056
N/A
0.442DataRank · unranked
18 citations

Johanna M. Sweere, Connor P. Healy, Natalia Sigal, Lichun Cheng, William D. Chronister +15 more

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

Signal Transduction and Targeted Therapy(2022)10.1038/s41392-022-01030-x
N/A
0.406DataRank · unranked
14 citations

Xu Wang, Xuexiang Du, Yan Zhang, Chunxia Ai, Siwen Hu‐Lieskovan +5 more

New‐onset prediabetes/diabetes worsens overall survival in patients with cancer: A real‐world retrospective cohort study

Diabetes Obesity and Metabolism(2025)10.1111/dom.70311
N/A
0DataRank · unranked
5 citations

Svenja Pauleck, Stephanie Richardson, Richard Viskochil, Prasoona Karra, Howard Colman +7 more

Comparison of QuPath and HALO Platforms for Analysis of the Tumor Microenvironment in Prostate Cancer

Laboratory Investigation(2025)10.1016/j.labinv.2025.104246
N/A
0DataRank · unranked
2 citations

Qin Zhou, Jonathan V. Nguyen, Érika Said Abu Egal, Qian Yang, Michael R. Freeman +5 more

Polymer-based chemo-immunotherapy: Combining immunogenic cell death induction and PD-L1 blockade enhances antitumor immunity in melanoma

Journal of Controlled Release(2025)10.1016/j.jconrel.2025.114193
N/A
0DataRank · unranked
3 citations

Hasan Al Faruque, Emilio Cortes-Sanchez, Matthew W. VanBrocklin, Siwen Hu‐Lieskovan, Morgan L. Cina +4 more

Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma

Current Oncology(2025)10.3390/curroncol32030144
N/A
0DataRank · unranked
2 citations

Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Berit Gibson, Umang Swami, Alyssa Erickson‐Wayman +14 more

Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1409
N/A
0DataRank · unranked
148 citations

Gabriel Abril-Rodríguez, Ameya S. Champhekar, Jennifer Tsoi, Katie M. Campbell, Anusha Kalbasi +16 more

Comparison of QuPath and HALO platforms for analysis of the tumor microenvironment in prostate cancer

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.05.16.654590
N/A
0DataRank · unranked
0 citations

Qin Zhou, Jonathan V. Nguyen, Érika Said Abu Egal, Qian Yang, Michael R. Freeman +5 more

Optimizing nucleic acid extraction and transcriptome evaluation from low-input, fixed clinical samples

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.06.02.122150
N/A
0DataRank · unranked
0 citations

Egmidio Medina, Ignacio Baselga-Carretero, Yaroslav Teper, Rangasamy P. Elumalai, Raymond J. Miller +15 more

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001781
N/A
0DataRank · unranked
35 citations

Jordan P. McPherson, Benjamin Haaland, Kenneth F. Grossmann, Carolyn Luckett, Benjamin Newell Voorhies +6 more

First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma

Cancer Reports(2021)10.1002/cnr2.1419
N/A
0DataRank · unranked
10 citations

Benjamin Haaland, Siwen Hu‐Lieskovan, Howard Colman, Sheri L. Holmen, Xuechen Wang

1033TiP A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies

Annals of Oncology(2021)10.1016/j.annonc.2021.08.1417
N/A
0DataRank · unranked
4 citations

Timothy A. Yap, Sarina A. Piha‐Paul, Patricia LoRusso, Siwen Hu‐Lieskovan, Christopher J. Shepherd +6 more

Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis

Research Square(2023)10.21203/rs.3.rs-2997157/v1
N/A
0DataRank · unranked
1 citations

Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Berit Gibson, Umang Swami, Alyssa Erickson‐Wayman +14 more

Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials

The Oncologist(2024)10.1093/oncolo/oyae012
N/A
0DataRank · unranked
5 citations

Ching-Nung Lin, Samuel S. Coleman, Arabella Young, Abdul Rafeh Naqash, Siwen Hu‐Lieskovan +2 more